Articles: function.
-
Pleural Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Patients coming for preoperative evaluation are often diagnosed for first time with underlying diseases that go unnoticed unless patients present for evaluation. One such example is hypoxia. We present 74 year-old male with no significant past medical history coming for preoperative evaluation for cataract surgery and was hypoxic. With careful assessment of history and physical exam along with imaging revealed asbestosis, thus highlighting importance of occupational exposure. ⋯ The following authors have nothing to disclose: Meenal Malviya, Asad Omar, Navneet Kumar, Muhammad EhteshamNo Product/Research Disclosure Information.
-
BronchiectasisSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: To assess the effectiveness of inhaled colistin in elderly patients with bronchiectasis and chronic bronchial PA infection in reducing hospital readmissions ⋯ The following authors have nothing to disclose: Eva Tabernero, Pilar Gil, Ramon Alkiza, Javier Garros, Anibal Hernandez, Juan Luis ArtolaNo Product/Research Disclosure Information.
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: The ILLUMINATE study evaluated the superiority of once-daily QVA149 110/50μg, a dual bronchodilator combining the LABA indacaterol and LAMA glycopyrronium, compared to twice-daily LABA/ICS, salmeterol/fluticasone 50/500μg (SFC), in terms of efficacy, safety and tolerability in patients with moderate-to-severe COPD. This analysis reports the efficacy and safety of QVA149 versus SFC in the sub-group population using fixed-dose LABA/ICS prior to study enrollment. ⋯ Karen Mezzi: Employee: Novartis Employee John Pallante: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Rare Disease Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Amyloid Cardiomyopathy is characterized by bi-ventricular thickening due to amyloid deposition leading to diastolic dysfunction. ⋯ Cardiac amyloidosis should be considered in any adult with unexplained heart failure and an echocardiogram showing increased wall thickness with a nondilated left ventricular cavity, particularly when associated with low voltage on electrocardiogram.Reference #1: N/ADISCLOSURE: The following authors have nothing to disclose: Sameer Chadha, On Chen, Sunday Olatunde, Adnan Sadiq, Gerald Hollander, Jacob ShaniNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The aim of our study was to look for the factors that affect survival of patients with COPD exacerbations admitted in a pulmonology department of a Portuguese central hospital. ⋯ The following authors have nothing to disclose: Daniel Coutinho, Inês Franco, Margarida Dias, Maria Tzer, Maria BritoNo Product/Research Disclosure Information.